Southern Company (The) Series 2 (SOJE)vsVersamet Royalties Corporation Common Stock (VMET)
SOJE
Southern Company (The) Series 2
$17.35
+0.58%
NONE · Cap: $65.72B
VMET
Versamet Royalties Corporation Common Stock
$12.18
+3.75%
NONE · Cap: $1.29B
Smart Verdict
WallStSmart Research — data-driven comparison
VMET leads profitability with a 58.5% profit margin vs 0.0%. VMET earns a higher WallStSmart Score of 45/100 (D+).
SOJE
Avoid25
out of 100
Grade: F
VMET
Hold45
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Keeps 59 of every $100 in revenue as profit
Strong operational efficiency at 135.6%
Revenue surging 465.2% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : SOJE
The strongest argument for SOJE centers on Market Cap.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.5% and operating margin at 135.6%. Revenue growth of 465.2% demonstrates continued momentum.
Bear Case : SOJE
The primary concerns for SOJE are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : VMET
The primary concerns for VMET are EPS Growth, Market Cap, P/E Ratio. A P/E of 56.6x leaves little room for execution misses.
Key Dynamics to Monitor
SOJE profiles as a value stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 465.2% — sustainability is the question.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VMET scores higher overall (45/100 vs 25/100), backed by strong 58.5% margins and 465.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Southern Company (The) Series 2
NONE · NONE · USA
Southern Company Series 2 is a prominent entity in the utility sector, specializing in the provision of reliable and sustainable energy solutions primarily across the Southeastern United States. As a subsidiary of the larger Southern Company, it benefits from a solid financial footing and a diversified energy mix that includes natural gas, nuclear, and renewable resources. The company's forward-thinking approach to innovation and dedication to environmental stewardship positions it strategically for the ongoing energy transition, thus appealing to institutional investors. Additionally, its strong regulatory framework and commitment to enhancing energy infrastructure further equip Southern Company Series 2 to navigate the evolving challenges of the energy market effectively.
Versamet Royalties Corporation Common Stock
NONE · NONE · USA
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?